These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29172255)

  • 1. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes.
    Kuwata H; Okamoto S; Seino Y; Murotani K; Tatsuoka H; Usui R; Hamamoto Y; Kurose T; Seino Y; Yabe D
    J Diabetes Investig; 2018 Sep; 9(5):1153-1158. PubMed ID: 29172255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
    Oh TJ; Jung HS; Bae JH; Kim YG; Park KS; Cho YM; Park KS; Kim SY
    J Korean Med Sci; 2013 Jun; 28(6):881-7. PubMed ID: 23772153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study.
    Yamakawa T; Sakamoto R; Takahashi K; Suzuki J; Matuura-Shinoda M; Takahashi M; Shigematsu E; Tanaka S; Kaneshiro M; Asakura T; Kawata T; Yamada Y; Osada UN; Isozaki T; Takahashi A; Kadonosono K; Terauchi Y
    J Diabetes Investig; 2019 Mar; 10(2):309-317. PubMed ID: 30070047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.
    Bouchi R; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 29054111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a Moderate Carbohydrate-Restricted Diet on DPP-4 Inhibitor Action among Individuals with Type 2 Diabetes Mellitus: A 6-Month Intervention Study.
    Kobayashi M; Miura T; Miura K; Hiroyama N; Akashi K
    J Nutr Sci Vitaminol (Tokyo); 2020; 66(2):114-118. PubMed ID: 32350172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Chen YW; Wang JS; Sheu WH; Lin SY; Lee IT; Song YM; Fu CP; Lee CL
    PLoS One; 2017; 12(2):e0171753. PubMed ID: 28182722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
    J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
    Watanabe T; Temma Y; Okada J; Yamada E; Saito T; Osaki A; Shimda Y; Matsumoto S; Horiguchi K; Ishida E; Kondo Y; Okada K; Takamizawa T; Nakajima Y; Ozawa A; Okada S; Horigome M; Yamada M
    Endocr J; 2021 May; 68(5):599-603. PubMed ID: 33408313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
    Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
    Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Tahara N; Yamagishi SI; Bekki M; Kodama N; Nakamura T; Sugiyama Y; Oshige T; Kumashiro Y; Honda A; Tahara A; Igata S; Fukumoto Y
    Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes.
    Maeda H; Kubota A; Kanamori A; Tanaka Y; Terauchi Y; Matsuba I;
    Diabetes Res Clin Pract; 2015 Jun; 108(3):e42-5. PubMed ID: 25836945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
    Okada S; Okada K; Okada J; Kikkawa K; Yamada E; Saito T; Andou T; Ohshima K
    Diabetes Metab Syndr; 2023 Jul; 17(7):102806. PubMed ID: 37343509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
    Huang CH; Huang YY; Hsu BR
    Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.